Cellular Biomedicine Group - CBMG Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$19.75
+0 (0.00%)
Get New Cellular Biomedicine Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CBMG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CBMG

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cellular Biomedicine Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $19.75.

This chart shows the closing price for CBMG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Cellular Biomedicine Group. This rating has held steady since July 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/13/2020Robert W. BairdDowngradeOutperform ➝ Neutral$28.00 ➝ $19.00High
7/13/2020Robert W. BairdUpgradeNeutral ➝ Outperform$19.00 ➝ $28.00High
3/4/2020BTIG ResearchDowngradeBuy ➝ NeutralMedium
11/12/2019Robert W. BairdDowngradeOutperform ➝ Neutral$26.00 ➝ $19.00Medium
9/17/2019BTIG ResearchInitiated CoverageBuy$19.00 ➝ $19.00Low
6/25/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$27.00 ➝ $27.00High
2/6/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$26.00Low
10/14/2018B. RileySet TargetBuy$38.00High
10/3/2018B. RileyBoost TargetBuy ➝ Buy$32.00 ➝ $38.00High
6/15/2018Maxim GroupReiterated RatingHoldLow
5/21/2018B. RileySet TargetBuy$32.00Medium
3/16/2018B. RileyReiterated RatingBuyLow
3/8/2018B. RileyInitiated CoverageBuy ➝ Buy$32.00Low
3/6/2018Maxim GroupReiterated RatingHoldMedium
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/12/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/11/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/10/2022
  • 7 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/9/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2022
  • 12 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
1/8/2023
  • 8 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 8 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Cellular Biomedicine Group logo
Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.
Read More

Today's Range

Now: $19.75
Low: $19.74
High: $19.75

50 Day Range

MA: $19.68
Low: $17.67
High: $19.75

52 Week Range

Now: $19.75
Low: $11.48
High: $19.75

Volume

8,375 shs

Average Volume

129,776 shs

Market Capitalization

$384.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Cellular Biomedicine Group?

The following Wall Street sell-side analysts have issued stock ratings on Cellular Biomedicine Group in the last year: StockNews.com.
View the latest analyst ratings for CBMG.

What is the current price target for Cellular Biomedicine Group?

0 Wall Street analysts have set twelve-month price targets for Cellular Biomedicine Group in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Cellular Biomedicine Group in the next year.
View the latest price targets for CBMG.

What is the current consensus analyst rating for Cellular Biomedicine Group?

Cellular Biomedicine Group currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CBMG.

What other companies compete with Cellular Biomedicine Group?

How do I contact Cellular Biomedicine Group's investor relations team?

Cellular Biomedicine Group's physical mailing address is 1345 AVENUE OF AMERICAS 15TH FLOOR, NEW YORK NY, 10105. The biotechnology company's listed phone number is 347-905-5663 and its investor relations email address is [email protected] The official website for Cellular Biomedicine Group is www.cellbiomedgroup.com. Learn More about contacing Cellular Biomedicine Group investor relations.